Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
551 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT00451555 | Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer | completed | Phase 2 | 156 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 1, 2019 | clinicaltrials |
| NCT01763788 | A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 192 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02221882 | A Study of LY3164530 in Participants With Cancer | completed | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01602224 | A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | completed | Phase 2 | 220 | Eli Lilly and CompanyINDUSTRY | 15 | Oct 8, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT01606748 | A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin | completed | Phase 2 | 35 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT01703091 | A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 197 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT01983878 | A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT01490632 | A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis | completed | Phase 2 | 271 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 27, 2019 | clinicaltrials |
| NCT02941601 | A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2019 | clinicaltrials |
| NCT00721162 | Study of Ramucirumab in Ovarian Cancer | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT00913835 | A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | completed | Phase 2 | 125 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01063075 | A Study in Advanced Solid Tumors | completed | Phase 2 | 34 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT01099358 | Study in Advanced Solid Tumors | completed | Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01081041 | A Study in Head and Neck Cancer | completed | Phase 2 | 187 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 25, 2019 | clinicaltrials |
| NCT01165021 | A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT01168973 | A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | completed | Phase 3 | 1,253 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 25, 2019 | clinicaltrials |
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | completed | Phase 3 | 1,072 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 25, 2019 | clinicaltrials |
| NCT01107457 | A Study in Participants With Moderate to Severe Psoriasis | completed | Phase 2 | 142 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 24, 2019 | clinicaltrials |
| NCT00781911 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01204710 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | completed | Phase 2 | 123 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 20, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT01769391 | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 167 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 20, 2019 | clinicaltrials |
| NCT00490451 | A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 18, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT01416389 | A Study of LY2523355 in Participants With Breast Cancer | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01505530 | A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer | completed | Phase 2 | 125 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 18, 2019 | clinicaltrials |
| NCT01721044 | A Moderate to Severe Rheumatoid Arthritis Study(RA-BEACON) | completed | Phase 3 | 527 | Eli Lilly and CompanyINDUSTRY | 22 | Sep 18, 2019 | clinicaltrials |
| NCT01900652 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants(Chime) | completed | Phase 2 | 111 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 18, 2019 | clinicaltrials |
| NCT00988858 | A Study of Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 17, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01160744 | A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 280 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 13, 2019 | clinicaltrials |
| NCT01226485 | A Study in Advanced Cancer | completed | Phase 1 | 84 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 13, 2019 | clinicaltrials |
| NCT00078260 | A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer | completed | Phase 3 | 589 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00087711 | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 3 | 1,713 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 12, 2019 | clinicaltrials |
| NCT00191126 | Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC | completed | Phase 3 | 263 | Eli Lilly and CompanyINDUSTRY | 15 | Sep 12, 2019 | clinicaltrials |
| NCT00191243 | Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer | completed | Phase 2 | 237 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00295815 | Enzastaurin Versus Lomustine in Glioblastoma | completed | Phase 3 | 397 | Eli Lilly and CompanyINDUSTRY | 14 | Sep 12, 2019 | clinicaltrials |
| NCT01107444 | Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 180 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 11, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT01919398 | A Study of LY2940680 in Japanese Participants With Advanced Cancers | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02518113 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | completed | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 11, 2019 | clinicaltrials |
| NCT01469000 | A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 195 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 10, 2019 | clinicaltrials |
| NCT00620321 | A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 24 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 9, 2019 | clinicaltrials |
| NCT01282463 | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma | completed | Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2019 | clinicaltrials |
| NCT03988114 | A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer(proMONARCH) | withdrawn | Phase 4 | 0 | Eli Lilly and CompanyINDUSTRY | 9 | Sep 6, 2019 | clinicaltrials |
| NCT01234402 | Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients | completed | Phase 2 | 153 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials